HRT side effects: what to expect and when to call your clinician. - Reddit

Why do the two types of HRT have different side effects?

“HRT” covers two distinct clinical populations with different hormone protocols and therefore different side-effect profiles. The first is menopausal hormone therapy (MHT), typically estrogen with or without progestogen, for perimenopausal and postmenopausal women. The second is testosterone replacement therapy (TRT) for men with clinically documented low testosterone.

The side effects, risks, and monitoring requirements for these two populations are meaningfully different. This article covers both, clearly labeled.

What are the common side effects of estrogen-based HRT?

For women on estrogen-based hormone therapy — whether estrogen-only (for those who have had a hysterectomy) or combined estrogen-progestogen — the most common side effects reported in the first weeks to months of therapy include:

• Breast tenderness: One of the most frequently reported initial side effects. Typically peaks in the first four to six weeks and diminishes as the body adapts. Persistent or worsening breast pain warrants evaluation.
• Bloating and fluid retention: Estrogen promotes mild fluid retention, particularly early in therapy or with dose increases. Usually temporary.
• Nausea: More common with oral estrogen; significantly less common with transdermal (patch, gel, cream) formulations because the GI tract is bypassed.
• Irregular bleeding or spotting: In women with an intact uterus on combined therapy, breakthrough bleeding is common initially, particularly with continuous combined regimens. Heavy or persistent bleeding warrants evaluation.
• Headaches: Some women experience headaches during dose initiation or changes. Women with a history of migraines may find their pattern changes on HRT.
• Mood changes: Mood effects of hormone therapy are complex and bidirectional. Many women report improved mood stability. Some, particularly those sensitive to progestogen, report low mood or irritability. Route of administration and progestogen type can be adjusted.

What are the common side effects of testosterone therapy (TRT)?

For men on testosterone replacement therapy, the common side effects are distinct from estrogen-based therapy:

• Acne and oily skin: Testosterone stimulates sebaceous glands. Acne is one of the most consistently reported TRT side effects, particularly in the first months. Adjusting the dose or switching administration routes can help.
• Elevated hematocrit: Testosterone stimulates red blood cell production. Elevated hematocrit increases blood viscosity and is the primary safety endpoint monitored in TRT patients. This is why hematocrit monitoring at three months (and annually thereafter) is required, not optional.
• Fluid retention: Mild fluid retention, particularly around the ankles, is common in the first weeks of TRT and usually resolves.
• Suppression of endogenous production: Exogenous testosterone suppresses LH and FSH, which reduces the body’s own testosterone production and also reduces sperm production. This is expected and dose-dependent. Men who want to preserve fertility should discuss this explicitly with their clinician before starting TRT.
• Elevated estradiol: Testosterone converts to estradiol via aromatization. Some men aromatize heavily and develop symptoms of high estrogen (water retention, mood changes, gynecomastia) on TRT. This is managed by monitoring estradiol levels and adjusting the protocol if needed.
• Testicular atrophy: Reduction in testicular size is expected with exogenous testosterone due to suppression of LH signaling. This is reversible in most cases when TRT is discontinued, but reversibility and timeline vary.

What are the serious HRT risks and what does the evidence show?

The most important risk data for estrogen-based HRT comes from the Women’s Health Initiative (WHI) and its long-term follow-up studies. The key findings — properly contextualized:

• Breast cancer risk (combined therapy): Long-term use of combined estrogen-progestogen HRT is associated with a small increase in breast cancer risk. The magnitude is modest — comparable in absolute terms to the risk associated with drinking one alcoholic drink daily. Duration of use, age at initiation, type of progestogen, and individual risk factors all modify this.
• Endometrial cancer risk (estrogen-only): Unopposed estrogen in women with an intact uterus increases endometrial cancer risk. This is why progestogen is added for women who have not had a hysterectomy — it is not optional.
• Venous thromboembolism (VTE): Oral estrogen is associated with increased VTE risk. Transdermal estrogen (patch, gel, spray) has a significantly lower VTE risk than oral and is generally preferred for higher-risk individuals. This is a real consideration in route selection.
• Cardiovascular risk: The relationship between HRT and cardiovascular risk is complex and age-dependent. The “timing hypothesis” suggests that initiating HRT close to menopause may differ meaningfully in cardiovascular impact from initiating it a decade or more post-menopause. This is an active area of research and clinical debate.

For TRT, the most studied serious risks include hematocrit elevation (managed by monitoring), prostate tissue effects (managed by PSA monitoring and exclusion of active prostate cancer), and ongoing cardiovascular research. The FDA’s current labeling for testosterone products notes a possible increased risk of major adverse cardiovascular events; this remains an area of active study.

How does monitoring reduce HRT risk?

The majority of serious HRT risks are manageable with proper monitoring — which is why clinical supervision is not a formality but a clinical necessity. Here is what competent hormone therapy management looks like:

• Baseline labs before prescribing: For TRT: testosterone panel, hematocrit, PSA, estradiol. For estrogen HRT: hormone levels, metabolic panel, relevant screening (mammography per guidelines). Baseline data creates the reference point for monitoring.
• Three-month follow-up labs: Critical for catching hematocrit elevation on TRT early, and for confirming estradiol levels are therapeutic (not supra- or sub-physiologic) on estrogen therapy.
• Annual review: Once stable, annual labs and clinical review allow dose adjustments as physiology changes with age.
• Responsive dose adjustment: Side effects are often a dose or formulation signal. A clinician who simply authorizes refills without responding to side effect reports is not practicing appropriate care.

What should you do when HRT side effects appear?

Most HRT side effects are:

• Transient adjustment effects — expected in the first four to eight weeks, resolve on their own or with minor dose refinement.
• Protocol optimization signals — persistent side effects that indicate a dose or formulation adjustment would improve tolerability.
• Clinical red flags — chest pain, leg swelling or pain, severe headache, unexpected heavy bleeding, hematocrit above threshold. These require prompt evaluation, not watchful waiting.

The appropriate response to most non-urgent side effects is to notify your clinician at your next scheduled check-in (or sooner if they worsen) and allow them to evaluate whether a protocol adjustment is warranted. Stopping HRT abruptly without clinician guidance can cause its own symptoms.

Frequently asked questions